Cardiff Oncology's Participation at a Leading Healthcare Conference
In the vibrant world of biotechnology, Cardiff Oncology, Inc. (Nasdaq: CRDF) is taking significant strides towards innovative cancer treatments. This clinical-stage biotechnology firm, specializing in PLK1 inhibition, is gearing up to present at the highly anticipated Piper Sandler 37th Annual Healthcare Conference.
The Event Details
The conference is set to occur from December 2nd to 4th, where Cardiff Oncology's management will engage in a fireside chat and host one-on-one investor meetings. Mark Erlander, PhD and the CEO, will represent the company during these sessions. His insightful leadership and expertise will surely shed light on the exciting developments within their therapeutic pipeline.
Presentation Schedule:
Presenter: Mark Erlander, PhD (CEO)
Date: December 2
Time: 9:30 AM ET
Cardiff’s Innovative Approach to Cancer Therapy
At the heart of Cardiff Oncology's mission is an unwavering commitment to harnessing PLK1 inhibition as a targeted treatment approach. This methodology focuses on creating advanced therapeutic options for various cancers, aiming to improve patient outcomes significantly. The lead asset of the company, onvansertib, is making waves in clinical research. It is being rigorously evaluated in tandem with standard treatments for several critical indications.
Targeting Multiple Cancers
Onvansertib is currently being studied for application in RAS-mutated metastatic colorectal cancer (mCRC) and in ongoing trials for advanced pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC). This focused approach allows Cardiff Oncology to tackle specific vulnerabilities within tumors, aiming to overcome challenges such as treatment resistance and provide more effective clinical benefits than standard therapeutic protocols alone.
Continued Commitment to Research and Development
The future looks promising for Cardiff Oncology as it continues to conduct groundbreaking research and development in oncological therapies. The company's structured pipeline reflects an array of strategies designed to confront cancer head-on, utilizing cutting-edge science grounded in PLK1 inhibition. Their focus not only emphasizes innovation but also dedication to improving the overall standard of care for cancer patients.
Stay Informed with Live Webcasts
For those interested in keeping abreast with Cardiff Oncology’s progress and insights shared during the Piper Sandler Healthcare Conference, live webcasts will be provided. Attendees are encouraged to register for access and benefit from the invaluable information presented during these sessions.
Contact Information
If you’re looking for more information about Cardiff Oncology's innovative journey or wish to make inquiries, here is the contact information:
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
Email: jlevine@cardiffoncology.com
Investor Contact:
Candice Masse
Astr Partners
Email: candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
Email: abonanno@lyraadvisory.com
Frequently Asked Questions
What is Cardiff Oncology focused on?
Cardiff Oncology is dedicated to developing innovative cancer therapies using PLK1 inhibition.
Where will Cardiff Oncology present its findings?
They will present at the Piper Sandler 37th Annual Healthcare Conference held from December 2-4.
Who is representing Cardiff Oncology at the event?
Mark Erlander, PhD, the CEO of the company, will present at the conference.
How can I access the live webcast of the conference?
Interested parties can register for the webcast through the Cardiff Oncology website.
What are some cancer types Cardiff Oncology is targeting?
Cardiff focuses on various cancers including colorectal, pancreatic, lung, and breast cancers.
